Pharmaceutical intermediates
Tofacitinib Citrate Intermediates
4 pharmaceutical intermediates for Tofacitinib Citrate. Indication: Ankylosing Spondylitis (AS); Juvenile Rheumatoid Arthritis; Ulcerative Colitis; Psoriatic Arthritis; Rheumatoid Arthritis (RA).
About Tofacitinib Citrate
- Originator
- Pfizer Inc
- Indication
- Ankylosing Spondylitis (AS); Juvenile Rheumatoid Arthritis; Ulcerative Colitis; Psoriatic Arthritis; Rheumatoid Arthritis (RA)
- Approved Date
- 11/06/2012
- DS/DP
- 12/08/2025
Available intermediates
4 intermediates currently listed for Tofacitinib Citrate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| （3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine HCL | 1062580-52-2 | / | / |
| 4-Chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine | 479633-63-1 | / | / |
| 1-benzyl-4-methylpiperidin-3-one | 32018-96-5 | / | / |
| N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 477600-74-1 | / | / |
Building toward Tofacitinib Citrate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →